课题基金 / 基金详情

Gene therapy for familial amybidotic polyneuropathy by urtra-fundaoning artificial nucleic acids

Gene therapy for familial amybidotic polyneuropathy by urtra-fundaoning artificial nucleic acids
超基人工核酸基因治疗家族性淀粉样多发性神经病
批准号:
15390275
负责人:
ANDO Yukio
金额:
$7.49万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2004

项目摘要

项目成果

ANDO Yukio的其他基金

相似基金

相关文献

中文摘要
翻译
众所周知,瑞典的FAP患者的表型与其他国家的FAP患者有很大的不同。为了阐明原因,我们进行了以下研究。1.瑞典北部实况调查:共有神经科、眼科等8名内科医生赴瑞典北部考察患者的临床表现和生活方式。2.痕量金属研究:采集池塘水、河井水、自来水管道水,测定水中12种金属元素。3.单倍型研究:将瑞典FAP患者的单倍型与其他国家FAP患者的单倍型进行比较,结果表明,水中金属As浓度高于日本样本。在明年的这个项目中,AS对体外淀粉样蛋白形成的影响将在我们的淀粉样蛋白形成检测系统中进行检测。在临床表现方面,不出所料,大多数患者起病晚,临床表现非常轻微。在单倍型研究中,瑞典的FAP患者样本与日本、葡萄牙和西班牙的FAP患者样本在几个基因上显示出不同的单倍型,这表明除了环境因素的影响外,遗传背景的差异可能部分解释了表型差异。在这些点上,我们将在明年继续我们的研究项目。
英文摘要
It is well known that the phenotype of Swedish FAP patients is quite different from that in other countries' FAP patients. To elucidate the reason, we performed the following studies. 1.Fact-finding study in northern part of Sweden : totally 8 medical doctors, such as neurologists and ophthalmologists went to northern part of Sweden to check clinical manifestations of the patients and way of living. 2.Trace metal study : Water in pond, river well, and water from water pipes were collected to measure 12 metals in water. 3.Haplotype study : Haplotypes of Swedish FAP patients were compared with those in other countries' FAP patients.By the studies, of metals in water, As concentrations were extremely higher compared with those in Japanese samples. In this project in next year, effect of As on amyloid formation in vitro will be examined in our amyloid formation assay system. Concerning clinical manifestations, as we expected, most of the patients was late-onset, and clinical manifestations were very mild. In the haplotype study, Swedish FAP patient samples showed different haplotypes in several genes compared with those in Japanese, Portugal, and Spanish FAP patients, suggesting that inaddition to the effect by environmental factors, the difference of the genetic background may partially explain the phenotype difference.In these points we continue our research projects in the next year.
期刊论文(72)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1038/sj.gt.3302228
发表时间: 2004-05-01
期刊: GENE THERAPY
影响因子: 5.1
作者: [Nakamura, M, Ando, Y, Yamamura, K]
通讯作者: Yamamura, K
安東由喜雄: "神経難病の遺伝医療-FAPを中心にして-. 遺伝医療とカウンセリング-その現状と未来-"SOAMT News. 6. 40-51 (2004)
安藤幸雄:“顽固性神经系统疾病的基因医学 - 关注 FAP。基因医学和咨询 - 现状和未来”SOAMT 新闻 6. 40-51 (2004)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
安東由喜雄: "遺伝性アミロイドーシスの病態解析と治療"臨床病理. 51. 530-535 (2003)
安藤幸雄:《遗传性淀粉样变性的病理分析与治疗》《临床病理学》51. 530-535(2003)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
DOI: --
发表时间: 2004
期刊: Neurology 63
影响因子: --
作者: [Obayashi K, Ando Y, Nakamura M, Yamashita T, Ueda M, Haraoka K, Terazaki H, Uchino M]
通讯作者: Uchino M
共 25 条
    Control of amyloid neuropathy from the aspect of inflammation
    • 批准号:
      15K15195
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.41万
    • 财政年份:
      2015
    • 负责人:
      ANDO Yukio
    • 依托单位:
    Early diagnosis and analyses of the pathogenesis for amyloidosis with all our previous investigations
    • 批准号:
      24249036
    • 项目类别:
      Grant-in-Aid for Scientific Research (A)
    • 资助金额:
      $30.7万
    • 财政年份:
      2012
    • 负责人:
      ANDO Yukio
    • 依托单位:
    Analysis of autoantibodies for targeting pathogenesis and therapyof misfolding diseases
    • 批准号:
      23659303
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.41万
    • 财政年份:
      2011
    • 负责人:
      ANDO Yukio
    • 依托单位:
    Hepatocyte replacement therapy for familial amybidotic polyneuropathy combining iPS cells and gene-repair therapy
    • 批准号:
      21390270
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.73万
    • 财政年份:
      2009
    • 负责人:
      ANDO Yukio
    • 依托单位:
    国内基金
    海外基金
    Transthyretin异常沉积参与颈动脉硬化斑块形成作用机制研究
    • 批准号:
      81700393
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      20.0万元
    • 批准年份:
      2017
    • 负责人:
      梁文昭
    • 依托单位: